DiaMedica Therapeutics Inc. DMAC
Set alert
9.75 USD +0.46 +4.95%
As of Nov 3, 1:05 PM ET
9.38 Day range 9.76
5.25 52-week range 10.42
- YTD
- +22.49%
- 1 year
- +43.38%
- Open
- 9.38
- Prev close
- 9.29
- Mkt cap
- 525.78M
- Vol
- 60.62K
- Avg vol
- 184.80K
- EPS
- -0.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.38
- High
- 9.76
- Forward P/E
- -7.26
- Beta
- 1.46
- Short ratio
- 3.88
- Inst. own
- 31.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 4.69
- 200-d avg
- 3.61
- 1y target
- 7.00
1Y chart
Signals (59)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 12, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| RSI: Overbought | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Newest 20 of 59.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 7.00 -28.2% downside
Now 9.75
- Target (low)
- 6.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.1725 | -0.18 – -0.16 | -0.14 | -23.2% | 0 | 0.0% | 4 |
| Next quarter | -0.20 | -0.21 – -0.19 | -0.14 | -42.9% | 0 | 0.0% | 2 |
| Current year | -0.5925 | -0.60 – -0.58 | -0.60 | +1.3% | 0 | 0.0% | 4 |
| Next year | -0.79 | -0.89 – -0.68 | -0.5925 | -33.3% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 7, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 16, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 21, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Mar 21, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jun 22, 2023 | Oppenheimer | Upgrade | Perform | Outperform |
| Jul 7, 2022 | Lake Street | Maintained | — | Buy |
| Jul 7, 2022 | Craig-Hallum | Maintained | — | Buy |
| Jul 7, 2022 | Oppenheimer | Downgrade | Outperform | Perform |
| Jun 30, 2021 | Roth Capital | Maintained | — | Buy |
| Apr 8, 2021 | Oppenheimer | Initiated | — | Outperform |
| Feb 17, 2021 | Roth Capital | Initiated | — | Buy |
| Jul 8, 2020 | Maxim Group | Initiated | — | Buy |
| May 15, 2020 | Craig-Hallum | Maintained | — | Buy |